Volume Resuscitation in Cirrhosis With Sepsis Induced Hypotension
NCT ID: NCT05059795
Last Updated: 2025-09-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
350 participants
Study Classification
OBSERVATIONAL
Study Start Date
2020-02-01
Study Completion Date
2025-08-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In critically ill patients with liver disease like cirrhosis or ACLF, fluid therapy needs to be instituted after identification of patients who will be fluid responsive and initiate appropriate inotropes early to prevent the mortality associated with fluid overload.
The parameters and methodology used for assessing fluid responsiveness have been studied earlier, but the optimum method is not established. Existing recommendations based on data regarding fluid responsiveness and choice of fluid for resuscitation from intensive care units in general cannot be applied to those with liver disease as the hemodynamic alterations that occur with liver disease, presence of hypoalbuminemia at baseline and presence of cardiac dysfunction interfere with the conventional methods of fluid status assessment, fluid responsiveness as well as the response to different types of resuscitation fluids.
Therefore the investigators attempt to compare various methods to estimate current intravascular volume status of patient which could be helpful in guiding fluid therapy.
The parameters and methodology used for assessing fluid responsiveness have been studied earlier, but the optimum method is not established. Existing recommendations based on data regarding fluid responsiveness and choice of fluid for resuscitation from intensive care units in general cannot be applied to those with liver disease as the hemodynamic alterations that occur with liver disease, presence of hypoalbuminemia at baseline and presence of cardiac dysfunction interfere with the conventional methods of fluid status assessment, fluid responsiveness as well as the response to different types of resuscitation fluids.
Therefore the investigators attempt to compare various methods to estimate current intravascular volume status of patient which could be helpful in guiding fluid therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension
NCT02462902
Cirrhosis With Septic Shock
COMPLETED
NA
20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid in Cirrhosis With Sepsis Induced Hypotension
NCT05441878
Cirrhosis, Liver
Acute-On-Chronic Liver Failure
Shock, Septic
+1 more
UNKNOWN
PHASE4
Continuous Passive Paracentesis for Intra-abdominal Hypertension
NCT04322201
Ascites Hepatic
Cirrhosis, Liver
Hypertension, Intraabdominal
+2 more
UNKNOWN
NA
Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension
NCT06076330
Liver Cirrhosis
UNKNOWN
NA
Comparison of Colloid (20% Albumin) Versus Crystalloid (Plasmalyte) for Fluid Resuscitation in Cirrhotics With Sepsis Induced Hypotension.
NCT02721238
Cirrhosis With Sepsis
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives:
1. To compare the accuracy of central venous pressure and inferior vena cava dynamic assessment and lactate clearance for estimating adequacy of fluid resuscitation in patients with cirrhosis with sepsis induced hypotension .\[Time Frame at enrolment, 6 hours, 24 hours\]
2. Predictors of all-cause mortality at Day 7 and day 28. \[Time Frame Day 7 and Day 28\]
PATIENTS AND METHODS Study Design: A Prospective observational study
Case Definition:
Cirrhosis will be defined by - "clinical features consistent with chronic liver disease (CLD) including a consistent history as well as a documented complication of CLD (i.e., ascites, varices, hepatic encephalopathy) and/or imaging results consistent with cirrhosis and/or liver histologic findings consistent with cirrhosis" ACLF will be defined as per EASL criteria with documentation of organ failures.
Systemic Inflammatory Response Syndrome (SIRS) - 2 more of following 4
1. Oral temperature \>38.3oC or \<36oC
2. Heart Rate \> 90 beats/min
3. Respiratory Rate \>20 breaths/min or PaCO2 \<32mmHg
4. WBC count \>12000/cumm, \<4000/cumm or \>10% immature band forms Sepsis is a SIRS in response to proven or suspected microbial event 'Sepsis induced hypotension' implies mean arterial pressure \< 65 mmHg or a reduction of \>40 mm Hg from baseline in the absence of other causes of hypotension Severe sepsis - sepsis-induced tissue hypoperfusion or organ dysfunction (any of the following thought to be due to the infection)
* Sepsis-induced hypotension
* Lactate above upper limits laboratory normal
* Urine output \< 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation
* Acute lung injury with PaO2/FIO2 \< 250 in the absence of pneumonia as infection source
* Acute lung injury with PaO2/FIO2 \< 200 in the presence of pneumonia as infection source
* Creatinine \> 2.0 mg/dL (176.8 μmol/L)
* Bilirubin \> 2 mg/dL (34.2 μmol/L)
* Platelet count \< 100,000 μL
* Coagulopathy (international normalized ratio \> 1.5) Septic shock is "sepsis induced hypotension despite adequate fluid resuscitation along with organ dysfunction or perfusion abnormality".
Acute kidney injury (AKI) is defined as any of the following:
1. Increase in SCr by ≥0.3 mg/dl (≥26.5 μmol/l) within 48 hours; or
2. Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
3. Urine volume \<0.5 ml/kg/h for 6 hours
Definition of Adequate Intravascular volume - IVC diameter ≥ 18mm and IVCCI \<40% Definition of Adequate fluid resuscitation - Achieving MAP ≥ 65mmHg with Fluid bolus
All patients eligible for the study will undergo screening as per the above criteria. The ones who satisfy the criteria will be counselled for participation in the study and written informed consent will be taken from the patient / the legal guardian in patients who are unable to do so. Patient information sheets will also be signed, briefing the patients about why the research work is necessary and also about the methodology.
Detail history and clinical examination will be done in all cases and the findings along with all investigation results will be recorded in a standard case record form. Information would be collected regarding the onset and duration of symptoms, etiology, and severity of disease, other baseline clinical features, demographic characteristics, routine biochemical and hematological investigations.
* After enrolment, baseline samples would be taken for routine investigations and samples for evaluation of sepsis - blood culture, urine culture, fluid cultures, procalcitonin will be taken.
* The patient would be assessed for 5 parameters and will be reassessed 30min and 4hours after starting fluid resuscitation.
1. IVC diameter and collapsibility Index
2. Serum lactate levels
3. Venous-arterial pCO2 difference
4. CVP where central line inserted as per treating physician's decision
5. ScVO2 where central line available
* The patients in septic shock where IVC diameter \<18mm or IVCCI≥40% in spontaneously breathing patients, would be regarded in fluid depleted state and will be given aggressive fluid resuscitation with 20% albumin 100 ml started within 30 min which is a standard fluid of choice in patients with cirrhosis and other fluids - Normal Saline/ balanced salt solution 30ml/kg over 3hrs.
(The patients who not fulfil above criteria would be assumed in a fluid replete state and be started on maintenance fluid management along with inotrope support as per standard dosage guidelines) Norepinephrine would be 1st choice vasopressor - started at a dose of 4μg/min and titrated every 20 min to a maximum of 21.3μg/min. If MAP still \<65mmHg, Vasopressor would be added starting from a 0.01U/min to 0.04U/min. Adrenaline would be added in shock refractory to both vasopressors in dose of 4-24μg/min.
* Along with fluid and inotrope support, the patient will also receive standard of care including empiric broad spectrum antibiotics, oxygen support/ventilator support if needed.
* MAP would be rechecked 30 min after starting fluid therapy. IVC diameter and IVCCI would also be checked at same time to see if change in MAP (if any) is reflected in the IVC status. Adequate fluid resuscitation would be defined by achieving a MAP ≥ 65mmHg. In patients achieving MAP≥65mmHg, fluid therapy will be continued. The patients still having MAP\<65 mmHg will be started on inotrope support according to standard guidelines.
* IVC, IVCCI, Lactate, venous-arterial pCO2 difference, CVP and ScVO2 would be remeasured at 4 hrs.
* The patient would be the followed with serial examinations, calculations of SOFA score, CTP and MELD.
* Samples to test for sepsis such as procalcitonin, galactomannan, beta D Glucan and high sensitivity CRP will be done every 48-72 hours as determined by the treating clinician.
* Cultures for bacterial and fungal sepsis will be taken as per the Liver ICU protocol.
* If discharged earlier, for the purpose of 28-day mortality the patients' kin would be contacted telephonically.
* Data regarding total amount of fluids, type of fluids, urine output, dose and duration of inotropes, initiation of RRT, total days in ICU/Hospital, immediate cause of death (In case of mortality) would be noted.
Presence of Cirrhotic Cardiomyopathy as per updated 2020 CCMC criteria.
CCM is defined as systolic or diastolic dysfunction in the absence of alternative cardiac pathology in concordance with the Cirrhotic Cardiomyopathy Consortium (CCMC) criteria. 9 Systolic dysfunction was defined as an ejection fraction (EF) ≤50% or an absolute value of GLS \<18%. LVDD will be defined as presence of 3 of the following 4 criteria: septal early diastolic mitral annular flow velocity (e') \<7 cm/s, early diastolic transmitral flow to early diastolic mitral annular velocity (E/e') ≥15, left atrial volume index (LAVI) \>34 mL/m2, tricuspid jet maximum velocity \>2.8 m/s, in the absence of pulmonary hypertension and the presence of measurable early to late diastolic transmitral flow velocity (E/A) ratio (E/A \>2 = grade 3 \& E/A 0.8-2 = grade 2 LVDD). Persons meeting only 2 criteria will be termed as indeterminate for LVDD grade. 19
1. To compare the accuracy of central venous pressure and inferior vena cava dynamic assessment and lactate clearance for estimating adequacy of fluid resuscitation in patients with cirrhosis with sepsis induced hypotension .\[Time Frame at enrolment, 6 hours, 24 hours\]
2. Predictors of all-cause mortality at Day 7 and day 28. \[Time Frame Day 7 and Day 28\]
PATIENTS AND METHODS Study Design: A Prospective observational study
Case Definition:
Cirrhosis will be defined by - "clinical features consistent with chronic liver disease (CLD) including a consistent history as well as a documented complication of CLD (i.e., ascites, varices, hepatic encephalopathy) and/or imaging results consistent with cirrhosis and/or liver histologic findings consistent with cirrhosis" ACLF will be defined as per EASL criteria with documentation of organ failures.
Systemic Inflammatory Response Syndrome (SIRS) - 2 more of following 4
1. Oral temperature \>38.3oC or \<36oC
2. Heart Rate \> 90 beats/min
3. Respiratory Rate \>20 breaths/min or PaCO2 \<32mmHg
4. WBC count \>12000/cumm, \<4000/cumm or \>10% immature band forms Sepsis is a SIRS in response to proven or suspected microbial event 'Sepsis induced hypotension' implies mean arterial pressure \< 65 mmHg or a reduction of \>40 mm Hg from baseline in the absence of other causes of hypotension Severe sepsis - sepsis-induced tissue hypoperfusion or organ dysfunction (any of the following thought to be due to the infection)
* Sepsis-induced hypotension
* Lactate above upper limits laboratory normal
* Urine output \< 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation
* Acute lung injury with PaO2/FIO2 \< 250 in the absence of pneumonia as infection source
* Acute lung injury with PaO2/FIO2 \< 200 in the presence of pneumonia as infection source
* Creatinine \> 2.0 mg/dL (176.8 μmol/L)
* Bilirubin \> 2 mg/dL (34.2 μmol/L)
* Platelet count \< 100,000 μL
* Coagulopathy (international normalized ratio \> 1.5) Septic shock is "sepsis induced hypotension despite adequate fluid resuscitation along with organ dysfunction or perfusion abnormality".
Acute kidney injury (AKI) is defined as any of the following:
1. Increase in SCr by ≥0.3 mg/dl (≥26.5 μmol/l) within 48 hours; or
2. Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
3. Urine volume \<0.5 ml/kg/h for 6 hours
Definition of Adequate Intravascular volume - IVC diameter ≥ 18mm and IVCCI \<40% Definition of Adequate fluid resuscitation - Achieving MAP ≥ 65mmHg with Fluid bolus
All patients eligible for the study will undergo screening as per the above criteria. The ones who satisfy the criteria will be counselled for participation in the study and written informed consent will be taken from the patient / the legal guardian in patients who are unable to do so. Patient information sheets will also be signed, briefing the patients about why the research work is necessary and also about the methodology.
Detail history and clinical examination will be done in all cases and the findings along with all investigation results will be recorded in a standard case record form. Information would be collected regarding the onset and duration of symptoms, etiology, and severity of disease, other baseline clinical features, demographic characteristics, routine biochemical and hematological investigations.
* After enrolment, baseline samples would be taken for routine investigations and samples for evaluation of sepsis - blood culture, urine culture, fluid cultures, procalcitonin will be taken.
* The patient would be assessed for 5 parameters and will be reassessed 30min and 4hours after starting fluid resuscitation.
1. IVC diameter and collapsibility Index
2. Serum lactate levels
3. Venous-arterial pCO2 difference
4. CVP where central line inserted as per treating physician's decision
5. ScVO2 where central line available
* The patients in septic shock where IVC diameter \<18mm or IVCCI≥40% in spontaneously breathing patients, would be regarded in fluid depleted state and will be given aggressive fluid resuscitation with 20% albumin 100 ml started within 30 min which is a standard fluid of choice in patients with cirrhosis and other fluids - Normal Saline/ balanced salt solution 30ml/kg over 3hrs.
(The patients who not fulfil above criteria would be assumed in a fluid replete state and be started on maintenance fluid management along with inotrope support as per standard dosage guidelines) Norepinephrine would be 1st choice vasopressor - started at a dose of 4μg/min and titrated every 20 min to a maximum of 21.3μg/min. If MAP still \<65mmHg, Vasopressor would be added starting from a 0.01U/min to 0.04U/min. Adrenaline would be added in shock refractory to both vasopressors in dose of 4-24μg/min.
* Along with fluid and inotrope support, the patient will also receive standard of care including empiric broad spectrum antibiotics, oxygen support/ventilator support if needed.
* MAP would be rechecked 30 min after starting fluid therapy. IVC diameter and IVCCI would also be checked at same time to see if change in MAP (if any) is reflected in the IVC status. Adequate fluid resuscitation would be defined by achieving a MAP ≥ 65mmHg. In patients achieving MAP≥65mmHg, fluid therapy will be continued. The patients still having MAP\<65 mmHg will be started on inotrope support according to standard guidelines.
* IVC, IVCCI, Lactate, venous-arterial pCO2 difference, CVP and ScVO2 would be remeasured at 4 hrs.
* The patient would be the followed with serial examinations, calculations of SOFA score, CTP and MELD.
* Samples to test for sepsis such as procalcitonin, galactomannan, beta D Glucan and high sensitivity CRP will be done every 48-72 hours as determined by the treating clinician.
* Cultures for bacterial and fungal sepsis will be taken as per the Liver ICU protocol.
* If discharged earlier, for the purpose of 28-day mortality the patients' kin would be contacted telephonically.
* Data regarding total amount of fluids, type of fluids, urine output, dose and duration of inotropes, initiation of RRT, total days in ICU/Hospital, immediate cause of death (In case of mortality) would be noted.
Presence of Cirrhotic Cardiomyopathy as per updated 2020 CCMC criteria.
CCM is defined as systolic or diastolic dysfunction in the absence of alternative cardiac pathology in concordance with the Cirrhotic Cardiomyopathy Consortium (CCMC) criteria. 9 Systolic dysfunction was defined as an ejection fraction (EF) ≤50% or an absolute value of GLS \<18%. LVDD will be defined as presence of 3 of the following 4 criteria: septal early diastolic mitral annular flow velocity (e') \<7 cm/s, early diastolic transmitral flow to early diastolic mitral annular velocity (E/e') ≥15, left atrial volume index (LAVI) \>34 mL/m2, tricuspid jet maximum velocity \>2.8 m/s, in the absence of pulmonary hypertension and the presence of measurable early to late diastolic transmitral flow velocity (E/A) ratio (E/A \>2 = grade 3 \& E/A 0.8-2 = grade 2 LVDD). Persons meeting only 2 criteria will be termed as indeterminate for LVDD grade. 19
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cirrhosis, Liver
Sepsis
Acute on Chronic Liver Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cirrhosis/ACLF of any etiology
Albumin + electrolyte solution
Intervention Type
DRUG
Type of resuscitation fluid, dose and use of inotrope
POCUS guided fluid resuscitation
Intervention Type
DIAGNOSTIC_TEST
Conventional goal directed therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Albumin + electrolyte solution
Type of resuscitation fluid, dose and use of inotrope
Intervention Type
DRUG
POCUS guided fluid resuscitation
Conventional goal directed therapy
Intervention Type
DIAGNOSTIC_TEST
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Crystalloid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology
2. Hypotension (MAP \<65mmHg or SBP \<90mmHg)
3. 18-65 yrs of age
2. Hypotension (MAP \<65mmHg or SBP \<90mmHg)
3. 18-65 yrs of age
Exclusion Criteria
1. Already received colloid or 2 litres of fluid within the first 2 hours of presentation, without echocardiographic assessment.
2. Already on vasopressors/inotropes
3. Severe pre-existing cardiopulmonary disease
4. Acute Respiratory Distress Syndrome (ARDS)
5. Active bleeding like variceal bleed 28
6. Cerebrovascular events
7. Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy
8. Admission to ICU following liver transplantation, burns, cardiac surgery
9. Brain death or likely brain death within 24 hours
10. Previous adverse reaction to human albumin solution
11. Pregnant or lactating women
12. Informed consent refused by patient or attendants
2. Already on vasopressors/inotropes
3. Severe pre-existing cardiopulmonary disease
4. Acute Respiratory Distress Syndrome (ARDS)
5. Active bleeding like variceal bleed 28
6. Cerebrovascular events
7. Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy
8. Admission to ICU following liver transplantation, burns, cardiac surgery
9. Brain death or likely brain death within 24 hours
10. Previous adverse reaction to human albumin solution
11. Pregnant or lactating women
12. Informed consent refused by patient or attendants
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Post Graduate Institute of Medical Education and Research, Chandigarh
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Madhumita Premkumar
Assitant Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PGIMER
Chandigarh, Chandigarh, India
Site Status
Postgraduate Institute of Medical Education and Research
Chandigarh, , India
Site Status
Countries
Review the countries where the study has at least one active or historical site.
India
References
Explore related publications, articles, or registry entries linked to this study.
Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, Vauquelin P, Assous M, Sicot C. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med. 1992 Jun;20(6):746-50. doi: 10.1097/00003246-199206000-00008.
Reference Type
BACKGROUND
ARISE Investigators; ANZICS Clinical Trials Group; Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA, Williams P. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014 Oct 16;371(16):1496-506. doi: 10.1056/NEJMoa1404380. Epub 2014 Oct 1.
Reference Type
BACKGROUND
Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008 Jul;134(1):172-8. doi: 10.1378/chest.07-2331.
Reference Type
BACKGROUND
Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids? JAMA. 2016 Sep 27;316(12):1298-309. doi: 10.1001/jama.2016.12310.
Reference Type
BACKGROUND
Velissaris D, Pierrakos C, Scolletta S, De Backer D, Vincent JL. High mixed venous oxygen saturation levels do not exclude fluid responsiveness in critically ill septic patients. Crit Care. 2011 Jul 26;15(4):R177. doi: 10.1186/cc10326.
Reference Type
BACKGROUND
Lee YK, Hwang SY, Shin TG, Jo IJ, Suh GY, Jeon K. Prognostic Value of Lactate and Central Venous Oxygen Saturation after Early Resuscitation in Sepsis Patients. PLoS One. 2016 Apr 7;11(4):e0153305. doi: 10.1371/journal.pone.0153305. eCollection 2016.
Reference Type
BACKGROUND
Lee J, de Louw E, Niemi M, Nelson R, Mark RG, Celi LA, Mukamal KJ, Danziger J. Association between fluid balance and survival in critically ill patients. J Intern Med. 2015 Apr;277(4):468-77. doi: 10.1111/joim.12274. Epub 2014 Jun 27.
Reference Type
BACKGROUND
Sefidbakht S, Assadsangabi R, Abbasi HR, Nabavizadeh A. Sonographic measurement of the inferior vena cava as a predictor of shock in trauma patients. Emerg Radiol. 2007 Jul;14(3):181-5. doi: 10.1007/s10140-007-0602-4. Epub 2007 Jun 1.
Reference Type
BACKGROUND
Premkumar M, Rangegowda D, Kajal K, Khumuckham JS. Noninvasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility indices of the inferior vena cava using bedside echocardiography. JGH Open. 2019 Mar 12;3(4):322-328. doi: 10.1002/jgh3.12166. eCollection 2019 Aug.
Reference Type
BACKGROUND
Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J; LACTATE study group. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010 Sep 15;182(6):752-61. doi: 10.1164/rccm.200912-1918OC. Epub 2010 May 12.
Reference Type
BACKGROUND
Du W, Liu DW, Wang XT, Long Y, Chai WZ, Zhou X, Rui X. Combining central venous-to-arterial partial pressure of carbon dioxide difference and central venous oxygen saturation to guide resuscitation in septic shock. J Crit Care. 2013 Dec;28(6):1110.e1-5. doi: 10.1016/j.jcrc.2013.07.049.
Reference Type
BACKGROUND
Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt KD, Lee SS; Cirrhotic Cardiomyopathy Consortium. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2020 Jan;71(1):334-345. doi: 10.1002/hep.30875. Epub 2019 Oct 11.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Im/2019/2917
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Fluid Management Surgical Patients in Intensive Care Unit.
NCT03455296
COMPLETED
NA
Timing and Dose of Fluid Deresuscitation in Critically Ill Patients
NCT07275658
RECRUITING
Fluid Responsiveness Prediction at the Bedside
NCT00721604
COMPLETED
The Effect Of Resuscitation Guided By Two Different Dynamic Parameters On Time To Normalization Of The Capillary Refill Time In Adult Patients With Septic Shock
NCT06122909
COMPLETED
PHASE3
Effect of Fluid Deresuscitation With Central Venous Pressure Target 0-4 mmHg in Septic Shock Patients
NCT04156451
COMPLETED
NA
Restricted or Liberal Fluid for Haemodynamic Resuscitation in Sepsis
NCT05453565
NOT_YET_RECRUITING
Fluid Responsiveness Evaluation in Sepsis-associated Hypotension
NCT02837731
COMPLETED
NA
Cumulative Fluids Balance and Ventilator Associated Events
NCT05556694
COMPLETED
Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet
NCT00750516
WITHDRAWN
Peripheral Perfusion Versus Lactate Targeted Fluid Resuscitation in Septic Shock
NCT03762005
UNKNOWN
NA
Vexus-guided Fluid Management in Patients With Septic Shock After the Resuscitation Phase
NCT06227702
NOT_YET_RECRUITING
NA
The Enteral Resuscitation In Intensive Care Pilot- Study
NCT05595395
UNKNOWN
NA
Acute Hemodynamic Changes During Paracentesis
NCT02996188
COMPLETED
Impact of Fluid Resuscitation on Venous Congestion in Cardiac Critically-ill Patients
NCT07183397
NOT_YET_RECRUITING
Fluid Challenges in Intensive Care
NCT01787071
COMPLETED
Hemodynamic Optimization By Non-Invasive Determination Of Cardiac Output In Critically Ill Patients
NCT01309724
COMPLETED
NA
Estimating Fluid Requirement in Shocked Traumatic Patients by US on SCV
NCT06726668
NOT_YET_RECRUITING
Intrarenal Venous Flow Change During Fluid Removal in Critically Ill Patients: A Prospective Exploratory Study
NCT06216119
COMPLETED
Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock
NCT02473718
COMPLETED
NA
The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Critically Ill Patients
NCT01072071
UNKNOWN
NA
A Prospective Observational Study of the Expectations and Physiological Effects of Fluid Bolus Therapy
NCT03178578
UNKNOWN
Comparison Between Two Concentration of Hypertonic Saline in Intestinal Obstruction Surgery
NCT03741257
UNKNOWN
NA
Strong Albumin Solutions in Patients With Septic Shock
NCT05208242
COMPLETED
PHASE2/PHASE3
Comparing Fluid Responsiveness Assessment Methods in Patients With Impaired Consciousness
NCT06180902
RECRUITING
NA
Resuscitation Fluid Choice and Clinical Outcomes
NCT02641119
COMPLETED